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Background: In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased
determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently
verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the
information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific
antigen (PSA) testing for prostate cancer reduced the reviewers’ ability to correctly guess the trial arm.
Methods: Over 550 General Practitioner (GP) practices (>415,000 men aged 50–69 years) were cluster-randomised to
PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme
(control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical
vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial
phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for
their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the
extent of correct identification of trial arm.
Results: 1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments),
reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by
symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions
of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm
was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an
incorrect guess were equalised in each arm, following further standardisation.
Conclusions: It is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the
information submitted to them.
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In trials of cancer screening, where the primary outcome
is target cancer-specific mortality, the accurate deter-
mination of cause of death is crucial. The use of an inde-
pendent panel of experts to assign underlying cause of
death (UCD) following a review of medical notes is usu-
ally regarded, with the exception of autopsy, as the gold
standard [1-4] and in most countries is preferable to the
use of death certificates alone, where doubt may exist
about the overall quality of cause of death certification
[5-7]. This is especially true in trials where the popula-
tion is elderly with multiple, competing co-morbidities
or malignancies [8-10]. In these circumstances a degree
of misclassification of cause of death is inevitable, but if
this is unrelated to trial arm (non-differential misclassifi-
cation) then the effect of screening will be modestly
underestimated at worst [11]. However, substantial bias
such that the effect of screening is over or underesti-
mated may arise if misclassification is worse in one trial
arm than the other (differential misclassification). Differ-
ential misclassification may be avoided by blinding panel
experts to the trial arm a participant was in.
In cancer screening trials differential misclassification
may arise from two well-known sources of potential
death certificate bias. First, ‘sticking-diagnosis’ or attribu-
tion bias, which arises because more target cancers are
diagnosed in the intervention arm and therefore deaths
are more likely to be attributed to that cancer compared
to the control arm [1,12]. Secondly, deaths due to the
screening process itself which are not traced back to
screening but are certified as due to other causes will
lead to an overestimation of the beneficial effects of
screening [1,12]. Such ‘slippery-linkage’ bias might arise
from complications during the diagnostic process or
following specific therapeutic interventions for screen-
detected disease (such as complications following
surgery for the screen-detected cancer). The use of all-
cause mortality as an alternative endpoint avoids prob-
lems of attribution bias and includes unattributed deaths
due to screening, but requires very large numbers of trial
participants contributing many person-years of observa-
tion. For this reason, most cancer screening trials use
target cancer-specific mortality as the primary outcome,
while seeking to minimise the effect of these biases through
the review of medical notes and assignment of UCD by an
endpoint committee blind to allocation [13-15].
The accurate assignment of UCD by an endpoint com-
mittee requires identical methods of data collection
across trial arms and masking of reviewers to both the
allocated trial arm and the screening status of individ-
uals [1]. A major criticism of the early breast cancer
screening trials was that endpoint committee reviewers
were fully aware of which women had been screened
[16]. In cancer screening trials it is a challenge toconceal the trial arm from cause of death reviewers
without compromising the accurate verification of UCD.
Nevertheless, to optimise masking of trial arm, one guid-
ing principle should be that the type of information pre-
sented to reviewers must be standardised [1].
This paper investigated whether the standardisation of
information submitted to an endpoint committee for UCD
ascertainment in the ongoing Cluster randomised triAl of
PSA testing for Prostate cancer (CAP) (ISRCTN92187251)
successfully reduced the ability of reviewers in correctly
guessing the trial arm, thereby minimising any potential
biases arising from such guesses. Trained researchers ab-
stracted clinical information from medical records and
wrote short structured vignettes that were independently
reviewed by a team of clinicians, each of whom separately
assigned an UCD. To reduce bias in the verification
process, vignettes were carefully worded and followed spe-
cific rules aimed at concealing trial arm allocation from
cause of death reviewers, such that any misclassification
would be unrelated to trial arm. In addition to UCD as-
signment, reviewers were requested to guess trial arm allo-
cation, and to provide reasons for their guesses. These
reasons were used to revise vignette-writing rules and fur-
ther standardise information across trial arms, therefore re-
ducing any potential biases in the assignment of UCD
arising from the beliefs of reviewers about screening.
Methods
Study design
CAP is a randomised-controlled trial (RCT) that evaluates
the effectiveness and cost-effectiveness of population-
based prostate-specific antigen (PSA) testing for prostate
cancer in the UK. The primary outcome of the trial is
prostate cancer mortality at ten years (median) follow-up;
secondary outcomes are disease stage and grade, progres-
sion and all-cause mortality. The trial design (Figure 1)
has been reported fully elsewhere [17]. Briefly, between
2001 and 2007 over 550 General Practitioner (GP)
practices in eight centres in England and Wales were
cluster-randomised to either a single round of PSA test-
ing (intervention) or the National Health Service (NHS)
prostate cancer risk management programme [18].
Over 415,000 men aged 50–69 years were included,
representing approximately 8% of the male population
of England and Wales in this age group. Men in the
intervention arm diagnosed with localised prostate can-
cer through PSA testing were eligible to participate in
an embedded randomised-controlled trial - the ProtecT
(Prostate testing for cancer and Treatment) trial that
evaluates three treatments for clinically localised dis-
ease: active monitoring (regular PSA testing and re-
view), radical conformal radiotherapy and radical
prostatectomy (ISRCTN20141297) [19]. Approximately
59% of intervention arm men did not respond to the
Figure 1 CAP trial design. *Further n = 1451 excluded due to prostate cancer pre-randomisation, or failed to trace at HSCIC. **Further n = 1716
men excluded due to prostate cancer pre-randomisation, failed to trace at HSCIC, or refused.
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vited for a PSA test because they did not fulfil the Pro-
tect inclusion criteria (they were excluded by their GP
because of serious co-morbidity or severe mental ill-
ness) (Figure 1), and so followed standard NHS prostate
cancer risk management. All eligible men in CAP with-
out a pre-randomisation prostate cancer diagnosis were
identified and flagged with the regional cancer registries
and the Health and Social Care Information Centre
(HSCIC) for notification of subsequent cancer diagno-
ses, embarkations and deaths.Clinical vignettes
It was not feasible to review all deaths, which are ex-
pected to number over 80,000 during the 10 years of
follow-up for the primary outcome. The sub-set of
deaths reviewed followed pre-defined criteria adapted
from the Prostate, Lung, Colorectal and Ovarian (PLCO)
Cancer Screening Trial [1]. These criteria included all
men with an incident diagnosis of prostate cancer, re-
gardless of cause of death on the death certificate, and
all men with a certified cause of death potentially related
to prostate cancer (based on pre-specified ICD 9 or ICD
10 codes in parts 1 or 2 of the death certificate).Hospital medical records were scrutinised by trained
researchers to abstract clinical data onto a standardised
proforma, including: symptoms and signs of prostate
cancer presence and progression, diagnostic and moni-
toring tests, histological grade of cancer, tumour stage,
treatments received and outcome, complications of pros-
tate cancer and its treatment, and co-morbidities,
including other suspected or diagnosed cancers and car-
diovascular diseases. The researchers used this informa-
tion to write a short vignette for each case, arranged in
five sections relating to the clinical pathway (clinical fea-
tures at diagnosis; treatments received; prostate cancer
progression; progression of co-morbidities; end of life),
and followed by a summary section where a short over-
view was given (see Additional file 1). All researchers re-
ceived regular training in trial-specific methodologies,
such as data extraction and vignette writing, clinical fea-
tures of prostate cancer and other common co-
morbidities, histology and radiology reporting, as well as
the broader aspects of screening trials.
The Cause of Death Evaluation (CODE) Committee is
made up of ten external medically qualified reviewers
from various clinical specialities (Urology, Oncology,
Pathology and Palliative Medicine). A panel of up to four
members evaluated each vignette independently and
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the UCD to one of five categories: definite, probable, pos-
sible, unlikely and definitely not prostate cancer deaths,
using a pre-defined algorithm adapted from the PLCO
and European Randomized Study of Screening for Pros-
tate Cancer (ERSPC) trials [1,2]. For quality assurance, a
random 20% of each researcher’s vignettes were independ-
ently reviewed by a urologist for accuracy and complete-
ness using the original medical records, and feedback was
given to researchers. Additional information for quality as-
surance was collected from the CODE questionnaires and
required reviewers to subjectively rate the quality of vi-
gnettes for adequacy, relevance and clarity, based on a
Likert scale of 1–10 (where 1 = poor and 10 = excellent),
and to rate their confidence in their UCD decision, based
on a Likert scale of 1–5 (where 1 = not at all confident
and 5 = extremely confident).
Masking of trial arm
Researchers and CODE reviewers were blinded to infor-
mation on the death certificate. Researchers followed
specific rules when writing vignettes to mask trial arm
allocation and screening status, and sought to standard-
ise clinical information submitted for UCD ascertain-
ment. Initial rules (phase 1) prevented any mention of:
i) the ProtecT trial, ‘screening’, or words suggestive of, or
specific to, the treatment trial: e.g. ‘3 arm trial’ ; ‘informa-
tion appointment’; ‘randomisation’ ; ‘research nurse’ ;
’PSA doubling time’ ; or ‘active monitoring’ (a term used
in the ProtecT trial to describe one of three treatment
arms; the term ‘conservative treatment’ was to be used
instead); ii) participation in other clinical trials, since this
would indicate non-participation in the ProtecT trial;
and iii) source of original referral (e.g. GP or clinic). In
January 2011, in response to a query by the CAP Data
Monitoring Committee about the adequacy of reviewers’
blinding, the third rule was tightened so that vignettes
did not include any reference to the way in which a man
presented or his symptoms at diagnosis.
Several more rules were introduced in June 2011
(phase 2) to further standardise the information pre-
sented for UCD assignment: i) age at diagnosis was no
longer to be stated in the summary section as men in
the intervention arm attending PSA testing as part of
ProtecT were aged 50–69 years, whilst those in the con-
trol arm could be older at diagnosis; ii) only the PSA test
result at diagnosis, and the last three readings or signifi-
cant PSA measures (e.g. evidence of biochemical failure
to treatment) were to be presented to avoid the identifi-
cation of men allocated to the ‘active monitoring’ treat-
ment arm of ProtecT who received very regular and
frequent PSA tests; iii) ‘PSA at diagnosis’ was defined as
the reading closest to diagnosis (usually at trans-rectal
ultrasound (TRUS)/biopsy), rather than the result at theinitial PSA testing clinic (potentially identifying the
intervention arm) because some men in the control arm
were initially referred without having undergone a PSA
test; iv) for investigations at the time of presentation and
initial treatments, dates were to be reported in the for-
mat of mm/yyyy rather than dd/mm/yyyy. This was be-
cause men in the intervention arm diagnosed via PSA
testing may have followed a clearly identifiable pathway,
obvious by date (PSA, TRUS/biopsy, staging investiga-
tions, treatment), whereas in the control arm the se-
quence of investigations sometimes differed depending
on clinical presentation, and in some cases treatment
was initiated before all investigations were completed.
Reviewers’ feedback from the CODE questionnaires
was used to analyse whether standardised information
was being presented across both trial arms. For each as-
sessment, reviewers were asked “what arm of the trial
was this man in?” and given three possible options:
intervention (invited for PSA testing) arm, control arm
or unsure. They were also asked to give reasons for their
decision (free text). In this paper we examine the rea-
sons reviewers gave for their choice of trial arm and the
extent to which reviewers were able to correctly identify
trial arm allocation before (phase 1) and after (phase 2)
the revision of vignette writing rules.
Data analysis
Misclassifications due to a reviewer’s beliefs about
screening are unlikely to be differential if those partici-
pants the reviewer thinks are in a particular trial arm are
actually equally split between screening and control
arms. Hence the misclassifications due to beliefs about
screening are non-differential between the actual screen-
ing and control arms. We can explore this by looking
first at those participants the reviewer thinks are in the
screening arm and secondly at those participants the re-
viewer believes are in the control arm, and ascertaining
for each in turn if there are equal proportions that are
actually in the screening and control arms. By working
with percentages of participants who are truly in the
screening arm and, separately, who are truly in the con-
trol arm, then for participants thought by a reviewer to
be in the screening arm we are still looking for equal
percentages in the actual screening and control arms to
avoid differential misclassification. This is the case even
if different numbers of deaths in the two trial arms have
been through the review process.
Ethics approval
CAP has been approved by the Trent Multi-centre
Research Ethics Committee (MREC). Reference numbers
are: MREC/03/4/093 (12 February 2004) and 05/MRE04/
78 (24 November 2005). Approval for flagging of men in
the control arm and non-responders in the intervention-
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Advisory Group (PIAG) (now the Confidentiality Advisory
Group (CAG)), under Section 251 of the NHS Act 2006
(reference PIAG 4–09 (k)/2003).
Results
To January 2014, 1313 independent CODE reviewer as-
sessments of UCD for 605 cases (vignettes) were com-
pleted across both study arms. Of these, 1195 assessments
(553 cases) included data on the reviewer’s opinion of trial
arm (in the earliest assessments reviewers were not ques-
tioned about trial arm allocation). There were 96 assess-
ments (44 cases) that were excluded as they related to
vignettes written during the 6 month period between
January and June 2011 when there had been partial revi-
sion of the vignette rules. Of the remaining 1099 assess-
ments, 510 (212 cases) related to vignettes written during
phase 1 (prior to January 2011); and 589 assessments (297
cases) related to phase 2 (post-June 2011). The meanTable 1 Reasons given for choice of trial arm
Correct arm Reason given
1. Factors relating to initial presentation
a. Asymptomatic, low PSA test result, localised disease, early p
b. Symptomatic, high PSA test result, locally advanced/metast
late presentation
2. Study-specific factors
Intervention a. No formal prostate cancer diagnosis
arm b. PSA test not performed
c. Timing of PSA test, investigations or treatments
d. Presence of co-morbidities or other cancers
e. Investigations, treatments received
f. Other study-specific factors
3. No reason stated
(Total for each phase = 100%)
1. Factors relating to initial presentation
a. Asymptomatic, low PSA test result, localised disease, early p
b. Symptomatic, high PSA test result, locally advanced/metast
late presentation
2. Study-specific factors
Control a. No formal prostate cancer diagnosis
arm b. PSA test not performed
c. Timing of PSA test, investigations or treatments
d. Presence of co-morbidities or other cancers
e. Investigations, treatments received
f. Other study-specific factors
3. No reason stated
(Total for each phase = 100%)
Table 1 shows the reasons reviewers gave for their choice of trial arm, for correct, in
total percentages. Figures have been rounded so may not add up to 100%.quality score assigned to all vignettes by CODE reviewers
was the same for both phases (mean: 8.7), as was the re-
viewer’s confidence in their UCD assessment (mean: 4.5).
Phase 1
Table 1 shows the reasons reviewers gave for their
choice of trial arm in both phases. Because the trial is
ongoing, absolute numbers (i.e. of deaths by trial arm)
cannot be disclosed so the information is presented here
as percentages of the total number in each trial arm. In
phase 1, reviewers were unsure of trial arm allocation in
33% of intervention and 30% of control arm assess-
ments. Initially, decisions for the correct identification of
intervention arm men were based on the fact that men
were asymptomatic at presentation (10%), or because of
study-specific criteria that may have suggested the pres-
ence of screening, such as the timing of a PSA test result
preceding TRUS biopsy, or regular intervals between
PSA results (7%). It is important to recognise that sincePhase I (N = 510) Phase 2 (N = 589)
Correct Incorrect Unsure Correct Incorrect Unsure
10% 14% 1% 6% 24% 0%
resentation 10 2 0 6 3 0
atic disease, 0 12 1 0 21 0
8% 30% 4% 3% 22% 2%
0 3 0 0 2 0
0 21 0 0 11 0
4 5 2 1 2 1
0 0 1 0 4 1
3 0 0 1 2 0
1 1 1 1 1 0
3% 1% 25% 0% 1% 42%
21% 46% 33% 9% 46% 45%
14% 1% 1% 23% 3% 3%
resentation 1 1 1 0 3 1
atic disease, 13 0 0 23 0 2
50% 1% 4% 20% 2% 1%
8 0 1 1 0 0
31 0 1 10 0 0
6 1 1 2 1 0
1 0 0 3 0 0
2 0 0 1 1 1
2 0 1 3 0 0
4% 0% 25% 3% 0% 44%
68% 2% 30% 46% 6% 48%
correct and unsure categories; for both phases. Highlighted in bold are the
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did not accept the invitation for screening or were ineli-
gible for screening and did not have a PSA test (see
Figure 1), cancers detected among ‘non-attendees’ would
be more akin to control arm cancers. Consequently,
intervention arm men were incorrectly assigned to the
control arm by reviewers because of the absence of a
PSA test (21%) or other study-specific criteria which
may have implied the absence of screening (9%), or be-
cause men were symptomatic at diagnosis (12%). Correct
decisions about the control arm were also based on the
absence of either a PSA test result (31%), or prostate
cancer diagnosis (8%); or because men were symptom-
atic or had advanced disease at presentation (13%).
Phase 2
In phase 2 there was a reduction in the proportion of
correct guesses and much greater uncertainty: reviewers
were unsure of the trial arm in 45% of all intervention
and 48% of control arm assessments. Incorrect assign-
ment of intervention arm men to the control arm was
influenced by the absence of a PSA result (11%) or be-
cause the cancer had been detected at a much later bio-
logical stage than would be expected as a result of
detection by screening, for example, advanced disease at
presentation or a high PSA level (21%). Study-specific
criteria may have implied exclusion from the ProtecT
trial (such as previous cancers, multiple co-morbidities
and age at diagnosis). The correct identification of con-
trol arm men were based on factors such as advanced
disease at presentation or a high PSA test result (23%),
or the absence of a PSA test (10%).
Comparison of phases 1 and 2
During phase 1, for those participants thought by re-
viewers to be in the screening arm, Table 1 shows that
more of these participants were actually in the screening
arm (21%) than in the control arm (2%). Similarly, for
those participants thought to be in the control arm by
reviewers, more of these participants were in the control
arm (68%) than in the screening arm (46%). Conse-
quently, during Phase 1, misclassifications due to the re-
viewer’s beliefs about screening could be differential
between the two trial arms, and potentially bias esti-
mates of the effect of screening on prostate cancer
mortality.
The picture has changed during phase 2, Table 1
showing that for participants thought by reviewers to be
in the screening arm, 9% were but 6% were actually in
the control arm. For participants thought by reviewers
to be in the control arm, there were actually 46% in each
of the screening and control arms. Hence in this situ-
ation, any misclassifications due to the reviewer’s beliefs
about screening are likely to be non-differential acrossthe actual trial arms, and only a moderate underestimate
of the effect of screening on prostate cancer mortality
will result.
Discussion
Our analysis of 1099 assessments of 509 vignettes by an
endpoint committee of cause of death reviewers showed
that even relatively minor details, such as the timing and
sequence of investigations or treatments, gave clues
about the trial arm to which the man belonged. With
the further standardisation of the vignette-writing rules
in phase 2, the percentage of cases whereby reviewers
were unable to determine trial arm increased. The level
of uncertainty for the intervention arm men increased
from 33% in phase 1 to 45% in phase 2, while the level
of uncertainty for the control arm men increased from
30% in phase 1 to 48% in phase 2.
Importantly, the further standardisation of vignettes
would have likely shifted any misclassifications due to
reviewers’ belief about screening from differential to
non-differential across trial arms. The simple strategy of
vignette standardisation equalised and lowered the dif-
ference in the proportions of correct and incorrect trial
arm allocations (from 21% compared to 2% in phase 1 to
9% compared to 6% in phase 2 for intervention arm
guesses; and from 68% compared to 46% in phase 1 to
46% compared to 46% in phase 2 for control arm
guesses). Data from phase 2 showed that reviewers were
now just as likely to make an intervention arm guess
among intervention arm cases (and so guess correctly)
as they were to make an intervention arm guess among
control arm cases (and so guess incorrectly). Similarly,
there was equal likelihood of making a control arm
guess among control arm cases (and so guess correctly),
as of making a control arm guess among intervention
arm cases (and so guess incorrectly). This equalisation
should reduce any potential bias due to beliefs that the
reviewers may have about the effect of the intervention
on outcome (i.e. misclassifications are non-differential
across trial arms).
Despite the widely recognised importance of blinding
endpoint reviewers in order to reduce bias, blinding
methodologies are generally poorly reported [20,21]. A
recent comparison of the cause of death verification
process in four screening trials – the Health Insurance
Plan of New York breast screening trial (HIP), the Min-
nesota Colon Cancer Control Study of faecal occult
blood testing (MCCCS), and the Johns Hopkins (JHLP)
and Mayo Lung Projects (MLP) – found reviewers were
given access to all available medical information, includ-
ing the death certificates [22]. In later trials, more con-
certed efforts have been taken to conceal trial arm and
screening status from reviewers, through the submission
of edited copies of the clinical record, with all personal
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removed [1,2,4]. However, such efforts are not always suc-
cessful, with the treatment assignment (radical prostatec-
tomy versus observation) being correctly guessed for over
two-thirds of cases in the PIVOT trial, despite references
to trial arm being redacted before notes were sent to the
endpoint committee [23]. To achieve accurate adjudica-
tions, subtle clues to treatment assignment based on PSA
readings and imaging results could not always be removed.
In the CAP trial of population-based PSA testing for
prostate cancer, the standardisation of information sub-
mitted for UCD assignment across trial arms was opti-
mised through the use of short clinical summaries
written by trained researchers in the context of a rigor-
ous quality assurance process, rather than the submis-
sion of complete sets of medical notes for review, which
may be more difficult to standardise, not only because of
the sheer volume of data involved and prohibitive costs
of copying and screening records, but also because the
language used in hospital correspondence can give sub-
tle clues about screening status, however well-edited.
The strength of the CAP trial approach was in enabling
researchers to carefully word vignettes to conceal trial
arm and screening status, standardise terminology and
include the same level of detail across trial arms, while
providing sufficient information for accurate determin-
ation of UCD. In fact, even after the refinement of vi-
gnette writing rules, the quality of vignettes was not
compromised. The mean quality score assigned to all vi-
gnettes by CODE reviewers was the same for both phase
1 and phase 2 (mean: 8.7). Though some clinical data
were omitted from vignettes in order to achieve stand-
ardisation of information, this did not impact on the
confidence of reviewers in assigning UCD; the mean rat-
ing given by the reviewers for their confidence in their
UCD decision was 4.5 out of 5 in both phases (where
1 = not at all confident and 5 = extremely confident). In
addition, implementing such vignette-based blinding
procedures sped up the vignette writing process (rather
than demanding more time), as the amount of clinical
information presented became more streamlined with
standardisation.
In this study, our aim was not to measure blinding ef-
fectiveness, as such, using formal tests of blinding. In
fact in CONSORT 2010, mention of how the success of
blinding might be evaluated was specifically removed, in
view of the interpretational and measurement difficulties
[24]. In our study, we aimed to improve blinding qualita-
tively by reducing systematic error, rather than attempt-
ing to measure blinding success quantitatively, as we
recognise that it is difficult for such measurement to
yield meaningful interpretative data.
Our analysis raises two issues. First, the accurate as-
signment of UCD requires a careful balance to be struckbetween the amount and type of clinical information
presented and the adequacy of blinding achieved. Cancer
screening trials face inherent difficulties in this context,
since the rationale for population-based screening is the
detection of early cancers before they present clinically,
when potentially curative treatments are available [25].
Consequently in our analysis, reviewers were influenced
by low PSA test results or early or localised disease in
correctly identifying intervention arm men; whereas high
PSA test results or advanced disease at diagnosis were
frequently used as a basis for identifying control arm
men correctly. In cancer screening, other scenarios in-
volving the incidental diagnosis of the target cancer also
pose a challenge for masking trial arm without com-
promising UCD ascertainment: for example, where a
prostate cancer is diagnosed incidentally following a rad-
ical cystoprostatectomy for bladder cancer, the inclusion
of histological details might compromise blinding, but
the grade and stage of bladder cancer would be needed
to ensure accurate UCD assignment.
Secondly, as in many other studies, CAP uses the end-
point committee for final UCD assignment but have no
means of ascertaining if any misclassifications have oc-
curred at this level. Therefore it is not possible to determine
directly whether there are differential or non-differential
misclassifications. However, the results presented in this
report clearly demonstrate that vignette standardisation
moved the general trend from potential differential to non-
differential misclassifications, if any of this should occur.
Conclusions
In CAP, researcher-written vignettes were used to mask
external cause of death reviewers to the allocation of
trial arm in order to reduce any potential biases in the
verification of UCD. Feedback from the reviewers was
used to standardise and streamline the information pre-
sented to the endpoint committee for UCD assignment.
This has been shown to improve masking of trial arm
without compromising vignette quality. This finding is
particularly relevant to RCTs where the primary out-
come is cause-specific mortality determined by inde-
pendent cause of death review.
Additional file
Additional file 1: Vignette for cause of death review.
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